Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
JSON
Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Fotakis EA, Petrone D, Del Manso M, Siddu A, Stefanelli P, Bella A, Riccardo F, Rezza G, Palamara AT, Brusaferro S, Pezzotti P, Italian Integrated Surveillance of COVID-19 study group and of the Italian COVID-19 Vaccines Registry group
Euro Surveill 28 (32) - [2023-08-00; online 2023-08-10]
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.
PubMed 37561053
DOI 10.2807/1560-7917.ES.2023.28.32.2300397
Crossref 10.2807/1560-7917.ES.2023.28.32.2300397